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The design of toxicological testing strategies aimed at identifying the toxic effects of 
chemicals without (or with a minimal) recourse to animal experimentation is an important 
issue for toxicological regulations and for industrial decision-making. This article describes 
an original approach which enables the design of substance-tailored testing strategies with a 
specified performance in terms of false-positive and false-negative rates. The outcome of 
toxicological testing is simulated in a different way than previously published articles on the 
topic. Indeed, toxicological outcomes are simulated not only as a function of the performance 
of toxicological tests but also as a function of the physico-chemical properties of chemicals. 
The required inputs are QSAR predictions for the LOAELs of the toxicological effect of 
interest and statistical distributions describing the relationship existing between in vivo 
LOAEL values and results from in vitro tests. 
Our methodology is able to correctly predict the performance of testing strategies designed to 
analyze the teratogenic effects of two chemicals: Di(2-ethylhexyl)phthalate and 
Indomethacin. The proposed decision-support methodology can be adapted to any 
toxicological context as long as a statistical comparison between in vitro and in vivo results is 
possible and QSAR models for the toxicological effect of interest can be developed.  









In the framework of the European REACH (Registration, Evaluation, and Authorization of 
Chemicals) regulation it is expected that predictive tools will offer support in the screening 
and prioritization of chemicals for further toxicological testing (Benfenati, 2007). It is also 
expected that information obtained via alternatives to conventional animal testing should be 
considered during the different stages of decision-making provided that its reliability and 
pertinence can be proved (Grindon et al., 2006).  
In this context it is clear that computational models designed to simulate results generated by 
in vitro and in vivo toxicological tests could effectively support these expectations thanks to 
the insight they could provide before any experimental testing is carried out.    
The suitability of this computational approach is not limited to a regulatory framework but it 
can also be a valuable decision-support tool during the selection of candidate chemicals for 
the design of new products. Usually, several candidates show interesting properties but only a 
minority among them will maximize the desired property while minimizing unwanted 
toxicological side effect.  It is therefore crucial to weigh the pros and cons relative to options 
such as the cessation of a research project (because of unmanageable toxicological concerns) 
or the beginning of a thorough and costly toxicological investigation on few selected 
chemicals. 
Quantitative approaches for decision-making proved to be useful when applied to complex 
decisions in the toxicological field (Burman and Senn, 2003) but these methods in drug or 
chemical development are still in their infancy.  
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Currently, the problem is dealt with by having recourse to testing strategies that integrate 
different sources of toxicological information, such as data from in vivo, in vitro and in silico, 
approaches within a sound decision-making framework (Grindon et al. 2006).   
This overall approach can permit the toxicological characterization of chemicals with a 
minimal recourse to animal testing while ensuring a better protection of human health and the 
environment thanks to an efficient prioritization of chemicals for further toxicological testing.   
However, it is important noting that, during these stepwise procedures, information obtained 
at a given point of the strategy is not used to optimize the subsequent evaluation steps. In our 
opinion, an optimal tiered system would be a system in which the decision to be made after 
the completion of a step would not only be a choice between “stop testing” or “continue 
testing” but also a choice aimed at the rational selection of the test to be adopted for the 
subsequent evaluation. 
A theoretical basis for tiered tests has already been proposed based on a classical decision-
theoretical framework (Hansson and Ruden, 2007). It consists in utility maximization, this 
utility being a function of the values of true positives and true negatives and the disvalues of 
false negatives and false positives. The probability of true positives, true negatives, false 
positives and false negatives is assumed to be test dependent.  
In contrast, the methodology we propose in this paper computes these probabilities as a 
function of both the performance of toxicological tests and the physico-chemical properties of 
the chemicals to be analyzed. The rational for this approach is that the statistical simulation of 
toxicological testing can be carried out with increased certainty if a QSAR prediction can be 
obtained for a chemical of interest as we will describe in detail in section ****., 
Therefore, according to our methodology, an effective simulation of toxicological test results 
requires the quantification of the ability for a given test to detect toxicity as a function of the a 
priori probability for a chemical to be toxic.  
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An essential part of our approach relies, on the simulation of in vitro and in vivo test results 
by means of Monte Carlo sampling of two statistical distributions: the distribution that 
describes how the results yielded by alternative tests compare with results from a 
toxicological “gold standard” (in vivo results obtained via OECD guidelines for this article) 
and the distribution (obtained by means of QSAR modeling) describing the distribution of 
“gold standard” Lowest Observed Adverse Effect Levels (LOAELs) for the chemical under 
investigation. Thanks to this procedure the expected rate of false positives and false negatives 
is therefore derived for the chemical of interest. During the computational simulations, the 
uncertainties relative to the results of QSAR modeling and the simulation of toxicological 
testing are accounted for. At the end of the simulations, the testing strategies whose false 
positives and false negatives rates are below a specified threshold are selected. 
In order to illustrate our methodology, we devised testing strategies with respect to 
teratogenesis for two molecules: Di(2-ethylhexyl) phthalate (DEHP, used as a plasticizer in 
polyvinyl chloride plastics) and indomethacin (a non-steroidal anti-inflammatory drug).    
 
The evaluation of offspring for structural abnormalities comprising external, visceral and 
skeletal examinations is an essential branch of reproductive toxicology (OECD, 2000) and, as 
of now, three in vitro tests for developmental toxicity testing have been validated by the 
European Center for the Validation of Alternative Methods (ECVAM) for embryotoxicity 
screenings. The predictive performance of the tests was deemed to be generally satisfactory. 
These tests are the embryonic stem-cell test (EST, Genschow et al., 2004), the post-
implantation rat whole-embryo culture test (WEC, Piersma et al., 2004) and the micromass 
test (MMT, Spielmann et al., 2004). Although they are not capable of completely replacing 
the in vivo developmental toxicity tests, their use as screening tests (where positive results 
would negate the need for further testing) within a testing strategy could reduce the number of 
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animals required (Grindon et al., 2008) and the cost of the assessment of the developmental 
toxicity of substances requires by the REACH regulation. 
 
2. Materials and Methods 
 
2.1 Selection of chemicals for QSAR modeling 
Chemicals were selected from the database Registry of Toxic effects of Chemical Substances 
(RTCES). It is a database of toxicological information compiled, maintained, and updated by 
the National institute for Occupational Safety and Health (NIOSH). From RTECS we 
construct a database in the following way: first select the chemicals having an effect on 
embryo or fetus development (specific developmental abnormalities following a gavage 
administration of female rats). Second, we converted lowest published toxic doses (TDLo, the 
total dose amount administered to the pregnant female) in LOAELs (mg/kg bw/day).  
We only selected compounds which have been tested during the pregnancy of animals and the 
smallest LOAEL was retained if for the same compound, multiple LOAELs were available. 
LOAELs corresponding to single day exposures were discarded if data on multiple-day 
exposures were available. 
We based our work on LOAEL instead of NOAEL (No observed Adverse Effect Level) 
mainly because the availability of NOAEL values is rather limited. Secondly, a NOAEL that 
is not defined with respect to a LOAEL is not helpful. To be useful, NOAEL values have to 
be characterized as the highest level of exposure at which no adverse effects are detected and 
it is difficult to ascertain if this threshold has been reached without having defined the level of 
exposure at which the adverse effects begin to appear (WHO, 2000). Opinions on this subject 
differ, but the working consensus is that the level of exposure of concern in terms of human 
health is more adequately described by LOAEL values and this parameter was therefore 




2.2 QSAR modeling 
The 38 chemicals used to derive a QSAR model are reported in Table 1. LOAEL values were 
converted into decimal logarithmic values. Chemical structures were built and energy-
minimized thanks to the software “Molecular Modeling Pro Plus” licensed by ChemSw inc. 
Fairfield, CA (USA) and its quantum or molecular-mechanics modules.  
Molecules were processed with hydrogens and their stereochemistry coincides with the 
chirality information displayed by the website ChemIDplus lite 
(http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp).  
The simulations were carried out in a vacuum (i.e. without any water molecule around the 
organic molecules) and conformational analysis was carried before energy minimization by 
using the conformational energy routine of the software Molecualr Modeling ProPlus 
iteratively before the energy minimization with the MM2force field. 
After energy minimization, the MOPAC/AM1 semiempirical quantum mechanical 
calculations were used to generate atom partial charges and further optimize molecular 
conformations.  
 
2.2.1 Molecular descriptors. The majority of the selected chemicals are likely to induce 
teratogenic effects trough binding to diverse nuclear receptors but, as previous work showed 
(Liu et Gramatica, 2007; Giorgi et al., 2009; Wang et al. , 2008), binding to receptors can be 
adequately described without molecular docking calculations. Therefore, we adopted a 
receptor-independent approach and adopted the software DRAGON version 5.3 licensed by 
Talete srl, Milan (Italy) to compute molecular descriptors. Descriptors with a standard 
deviation less than 5% of the mean were deleted and the remaining 1352 descriptors were 




2.2.2 Selection of Training and Validation sets. Chemicals were hierarchically clustered 
according to descriptor similarity by means of the open source software “Cluster 3.0” 
downloaded from the webpage of the “Laboratory of DNA information analysis” at the Tokyo 
University (http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/software.htm). Descriptors were 
autoscaled before analysis. Centered correlation was adopted as similarity metrics when 
evaluating the clusters. Distances among items were computed by means of an average 
linkage. Eleven chemicals were chosen from the final branches of the hierarchical tree in 
order to cover both the descriptor space and the response range (i.e. the dependent variable).  
 
2.2.3 Genetic Algorithms. In order to select the descriptors that better correlates with the 
LOAEL to be modeled, we used Partial Least Squares regression and Genetic Algorithms 
(PLS-GA) that are implemented within the “PLS-toolbox” licensed by Eigenvector Research, 
Inc., WA (USA). The basic parameters used during the selection of the variables were as 
follows: 120 individuals, mutation rate =0.006 and double cross-over. Maximal number of 
generations and convergence were kept at a medium level (100% and 50% respectively) to 
avoid overfitting. The percentage of terms included in the initial variable subsets was set at 
10% with a penalty slope for the fitness equal at 0.05 in order to limit the number of variables 
included in the final model.  
The fitness function was implemented as the root-mean-square error of cross validation 
computed after a PLS regression that was allowed to include a maximum number of 3 latent 
variables. During the GA the PLS models were validated by means of leave several out cross-
validation computed by randomly splitting the dataset into 7 groups. The number of iterations 
for each cross-validation cycle was set at 10. Leave-several-out (7-groups) cross-validated R2 
(Q2) values and Response permutation analysis (y-scrambling, 100 permutations) were 





2.2.4 Probabilistic QSAR modeling. The orthogonal latent variables retained after the GA 
selection were used to define a Euclidean space that allowed us to derive a QSAR model that 
yielded predictions in terms of probability for a given chemical to be toxic together with its 
intrinsic certainty (ranging from 0 to 1) as described in Pery et al. (2009).  
In short, training set chemicals were divided into two categories (safe and toxic chemicals) 
according to a given threshold for LOAEL values. After this categorization, predictive 
certainty was described by Gaussian functions centered on each training set chemical so that 
certainty quickly decreased to zero for query chemicals that were far away from the training 
set. Each training set chemical contributed to predict the probability for the query chemical to 
be toxic and its contribution to predictive certainty was weighted with respect to the 
Euclidean distances (measured in the space described by the latent variables) separating the 
training set chemicals from the query chemical.  
The remaining uncertainty (equals to 1 minus the sum of the contributions to certainty from 
the training set) contributed to the prediction of toxicological probabilities by multiplying the 
fraction of toxic molecules in the training set. According to this procedure if uncertainty is 
equal at 1 (i.e. a non-informative QSAR) the toxicological probability coincides with the 
fraction of toxic molecules within the training set. The estimation of the width  of the 
Gaussians representing predictive certainty is obtained by maximizing the toxicological 
likelihood of the training set. The magnitude of  is related to the spatial organization of the 
space described by the latent variables. According to this methodology, when little can be 
inferred on the basis of chemical similarity, value and predictive certainty are very low and 
the predicted probability for a chemical to be toxic approaches the percentage of toxic 
chemicals in the training set. 
It is important to observe that QSAR modeling in our methodology is also used to construct a 
statistical distribution that describes how predictive certainty relates to the LOAEL values of 
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training set chemicals. This distribution has a central role during the simulation of testing 
strategies as described later in the article.  
 
2.3 Toxicological Tests for Teratogenesis 
We used data from teratogenic substances evaluated with OECD Guideline 414 and with the 
three validated in vitro assays (EST, WEC and MMT). 
The EST is based on the determination of inhibition of differentiation and growth. The 
embryotoxic potential of chemicals is determined by the evaluation of the inhibition of 
cardiac muscle differentiation of embryonic stem (ES) cells and the inhibition of growth of 
ES and 3T3 cells. The EST is performed with permanent cell lines from the mouse. 
In the WEC, post implantation rat embryos at early stages of organogenesis are cultured. At 
day 10 of gestation, pregnant rats are killed and embryos are isolated. Embryos are cultured 
for 48 hours in culture vessels and subsequently scored. This allows the identification of 
chemicals that induce embryotoxicity and malformations. 
The MM assay is a simple cell culture system, in which development and differentiation of 
embryonic limb buds cells are studied. Single cell suspensions are prepared from limb buds 
isolated from 13-days-old embryos. Undifferentiated mesenchyme cells of limb buds will 
form differentiation of foci of chondrocytes in micromass culture. Teratogenic compounds 
inhibit the formation of foci and can therefore be detected by a reduced number of foci, or a 
reduced number of cells within foci. Data which permit to compare in vivo and in vitro results 
are presented in Table 2. 
 
 
2.4 Simulation of testing strategies 
In tiered strategies, it is crucial to select test methods for lower tier test that minimize the 
probability of false negatives, while allowing for some false positives. False negatives can be 
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corrected at higher tiers, whereas false positives will not be corrected since they do not reach 
higher tiers (Hansson and Ruden, 2007).  
The aim of the decision-support methodology we propose is to simulate the final results of 
testing strategies, by integrating probabilistic QSAR model to the statistical simulation of 
toxicological testing in order to select only the testing strategies for which the levels of false 
positives and false negatives are below defined thresholds.  
A testing strategy is composed of successive tests to be executed in chronological order. At 
each step, if the result of the test is positive (i.e. the chemical is flagged as being toxic), then 
the strategy ends. If the result of the test is negative, then the following step is performed. 
Once that all the possible tests have been carried out the chemical is considered as not being 
toxic. In the framework of our methodology, the distinction between toxic and safe chemicals 
is determined by a comparison between the LOAEL (from in vivo rat experiments) values 
characterizing the chemicals and a given toxicological threshold, which could be, for instance 
an expected maximum exposure concentration. Chemicals for which LOAEL value is below 
this threshold are considered as toxic.  
 
The key question that our approach helps to answer is the following: “what battery of tests 
can assess the toxicity of chemicals of interest while ensuring a desired performance in terms 
of false positive and negative rates?” 
 
*.* The assumptions of the methodology 
The methodology we propose is based on five assumptions  
1) LOAEL values referring to the same sex, species and route of administration (rat, 
female and gavage in our case) adequately describe the toxicity of a molecule. 




3) A probability distribution for the LOAEL of a chemical can be derived by QSAR 
modeling 
4) The relative performance of an alternative test with respect to the in vivo “gold-
standard” (OECD guidelines in our case) can be adequately characterized by statistical 
distributions that describe the ratio between “gold-standard” LOAEL and results from 
an in vitro tests for a given set of molecules that have been tested by both methods.   
5) A testing strategy is composed of successive tests to be executed in chronological 
order. When the result of a test is positive (i.e. the chemical is flagged as being toxic), 
the strategy ends. If the result of the test is negative, a following step is simulated.  
 
 
*.* The underlying logic of the methodology 
A statistical distribution is derived for a given set of molecules that has been tested both in 
vivo and in vitro. This distribution describes the ratios of in vivo vs. in vitro results for each 
molecule composing the aforementioned set and they are an essential input of our 
methodology. Its role is to enable a comparison of the results yielded by in vitro tests and in 
vivo tests that are expressed in different units.  
In order to compute false positive/negative rates, the in vitro result obtained by means of MC 
sampling of this distribution (hereafter referred to as sim-LOAEL) has to be compared with 
the LOAEL that an in vivo experiments would yield if carried out for the query chemical 
(hereafter referred to as ref-LOAEL). The latter LOAEL value is obtained thanks to the 
sampling of a probability distribution for the in vivo LOAEL of the chemical under 
investigation that is determined by QSAR modeling. 
The simultaneous Monte Carlo sampling of these two distributions enables the simulation of 
the LOAEL values that an in vitro test and the gold-standard test would yield if carried out on 
the chemical under investigation (more details on the protocol are given in section *** and 
13 
 
***). In conclusion, the in vitro result is recognized as being a true/false positive or a 
true/false negative thanks to a comparison with the in vivo LOAEL and a user-defined 
LOAEL threshold that discriminates between safe and toxic chemicals. 
 
2.5 Simulation of “gold-standard” in vivo testing. Ref-LOAEL values for the query chemicals 
were simulated on the basis of the predictive certainties that characterize each chemical of the 
QSAR training set (calibrated with respect to “gold-standard” LOAELs) and that measures 
the predictive influence of each of them on the final prediction for the query chemical as 
described at paragraph 2.2.4.  
Thanks to this distribution of predictive certainties, the derivation of ref-LOAEL values was 
then performed in two steps. First, a random number between 0 and 1 is generated. If this 
number is below the percentage of predictive uncertainty estimated for the query chemical 
then a LOAEL (referred to as ref-LOAELfirst) is equiprobabilistically drawn from the 
LOAELs characterizing the chemicals that form the QSAR training set. If the number exceeds 
the percentage of uncertainty, the LOAEL is randomly selected among the LOAELs of the 
database with a frequency that will be proportional to the predictive certainties (Ct) estimated 
by QSAR modeling.  
In order to better approximate empirical testing we also introduced an extra source of 
uncertainty. Indeed, performing two times the same test (even a “gold standard”) would very 
likely result in slightly different outcomes. For this reason, the final ref-LOAEL value (ref-
LOAELfinal) is then sampled from a statistical distribution describing the ratio between two 
“gold-standard” LOAELs determined for the same chemical during two different runs of the 
same experimental protocol. To represent this experimental variability for the “gold-standard” 
test, we selected a loguniform distribution (i.e. the logarithm is uniformly distributed) 
centered on ref-LOAELfirst and with bounds equal at this value multiplied by three (upper 
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bound) and divided by three (lower bound). This choice is related to a gold standard test with 
selected exposure concentration in geometrical progression with a factor of three.    
 
2.6 Simulation of in vitro testing  
We simulated results of the gold standard in vivo test and of the three in vitro tests described 
at paragraph *.*. Before carrying out these simulations the distribution of the ratio between 
results of in vitro tests and the “gold-standard” test had to be described for a given set of 
reference chemicals. The sets of chemicals that were adopted for this pairwise comparison are 
reported in table 2.  
Two different statistical distributions were evaluated for the fitting of the ratios: loguniform 
and lognormal. The goodness of fit was determined by Chi-square tests and by a method 
specifically designed to assess uniformity of distribution even in the case where the data seem 
to be asymmetrically distributed (Afonso and Duarte, 1992). After the distribution was fitted, 
a ratio was randomly sampled. The sampled ratio was then multiplied by the median of the 
distributions to obtain “sim-LOAEL since results for in vitro tests are not expressed in the 
same units as “gold-standard” LOAELs”.  
When all this information was available, it was then possible to assess if the predicted 
LOAEL is a true positive, a true negative, a false positive or a false negative, by means of a 
comparison between ref-LOAELfinal, sim-LOAEL and the adopted toxicological threshold. 
For instance, if we have a LOAEL threshold equal at 50 mg/kg/day, a ref-LOAELfinal equal at 
40 mg/kg/day and a sim-LOAEL (e.g. from an in vitro test) equal at 80 mg/ml/day, the 
prediction will be regarded as being a false negative. A flowchart summarizing our 
methodology is reported in Figure 1.   
 




For a given toxicological threshold, we performed 10,000 simulations of LOAELs test results 
to estimate the rates of false positives and negatives for each test. The false positives and false 
negatives rates of the battery of tests were calculated as follows. The false negatives rate was 
equal at the product of the false negative rates of all tests in the battery, whereas the false 
positives rate of the testing battery was equal at one minus the product of one minus the false 
positive rate of each test. For instance, for a battery of tests composed by two tests 
characterized by a false positive and false negative rate equal at 0.1, the testing strategy would 
have a false negative rate of 0.01 and a false positive rate of 1-(1-0.1)*(1-0.1))= 0.19.  
 
2.7 Case study: DEHP  
DEHP, CAS RN 117-81-7) is a high production volume chemical used as a plasticizer in 
polyvinyl chloride plastics. It is found in a wide variety of consumer products, such as 
building products, car products, clothing, food packaging, children’s product, and in some 
medical devices made of polyvinyl chloride (Kavlock et al., 2006).  
We carried out our simulation of testing strategies as if no other information than QSAR 
predictions and statistical distributions describing the performance of toxicological tests were 
known. The results we obtained were finally compared with available in vivo and in vitro 
(WEC test, (Rhee et al., 2002)) data. 
We tested four exposure scenarios based on NTP-CERHR Expert panel report on the DEHP 
(2000). The first one corresponds to the range of general population exposure (3-30 10-3 
mg/kg/day), the second one (0.6 mg/kg/day) to long term exposure for adult hemodialysis, the 
third one to the highest possible exposure for medical use (3 mg/kg/day) and a fourth one 
corresponding to this latter use with a safety factor of 10.  
 
2.8 Case study 2: Indomethacin 
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Indomethacin (CAS RN 56-86-1) is a non-steroid anti-inflammatory and antipyretic agent 
(Hart and Boardman, 1963). It works by inhibiting the synthesis of prostaglandins in various 
tissues. It is known that it can cause constriction of the ductus arteriosus with pulmonary 
hypertension and right ventricular dysfunction in some fetuses and consequently the use for 
children is considered as dangerous (Lione and Scialli, 1995).  
Similarly to what was previously described for DEHP, we simulated testing strategies by 
integrating information yielded by QSAR modeling and then determined what testing strategy 
would keep the percentage of false positives and negatives at a reasonable level. This was 
finally compared with available in vivo and in vitro (WEC test) data.  
We tested four scenarios of exposure. The first one corresponds to the recommended use for 
an adult (about 25 mg per day, which we translated into 0.5 mg/kg/day). The second one 
corresponds to the maximum recommended use (200 mg per day, which we translated into 4 
mg/kg/day). The third and the fourth one correspond to maximum recommended use with 




3.1 Statistical distributions for the in vitro tests outputs 
Distributions parameters were estimated through mean and standard deviation estimates for 
the logarithm of the ratio values. For an uniform distribution [-A; A], the standard deviation 
equals A divided by the square root of 3. Statistical tests did not permit to reject neither 
lognormal or loguniform distributions but, when comparing the grouping of substances by 
groups of 5 and the statistical predictions, the loguniform distribution provided a better fit to 
the data. We obtained, respectively for WEC, MM and EST tests, the following intervals for 
uniform distribution of the logarithms of the ratio values, [-1.78; 2.58], [-2.42; 2.66] and [-
17 
 
2.55; 2.73] with result of the in vivo test expressed in mg/kg/day, and the result of in vitro 
tests in µg/ml. 
 
3.2 QSAR Modeling 
3.2.1 Partial Least Squares analysis 
We derived a PLS QSAR model as described in the materials and methods section. The model 
was characterized by two latent variables and its internal cross-validation (by leave-many-out 
validation) yielded a cross validated coefficient Q2lso equal at 0.68 indicating an internally 
predictive model. The response permutation plot displayed an R2Y intercept equal at 0.24 and 
a Q2Y intercept equal at -0.28 confirming the statistical significance of the model (Eriksson et 
al. 2003). An inspection of the plot representing the orthogonal latent variables (Fig. 2) 
revealed that Tetrachlorodibenzodioxin (TCDD) was an outlier whose leverage on the model 
is very high. Indeed, if this chemical was removed the inclusion of a second latent variable 
was still useful but Q2lso fell at 0.40. The probabilistic analysis of the outlier chemical that 
limited its influence in a rational way (i.e. by defining an applicability domain) will be 
described in the following paragraph together with the predictions for the external test set of 
chemicals.  
 
[FIG. 2 HERE] 
 
3.2.2 Probabilistic QSAR modeling 
The chemical space defined by the two latent variables of the PLS model allowed the 
application of the methodology described in Pery et al. (2009). A prerequisite for this 
methodology is that a toxicological threshold has to be defined in order to categorize 
molecules as being safe or toxic. For DEHP and Indomethacin the thresholds described in the 
Materials and Methods section were adopted and such a binarization allowed the estimation 
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of different values for the  parameter as reported in Table 3 and the prediction of 
toxicological probabilities and intrinsic certainty for the validation set as reported in Table 4. 
The values of the sigma parameter showed that the chemical space was structured and its 
smallest value is 0.24 times the average distance among all the molecules indicating a 
reasonable predictive quality of the dataset. Moreover, four phthalates populate the immediate 
neighborhood of DEHP (a phtalate belonging to the validation set) confirming the rational 
organization of the chemical space.  
Only predictions characterized by a certainty equal at 1 were regarded as belonging to the 
applicability domain of the model. This definition limited the validity of predictions only for 
query chemicals located in close proximity of the training set molecules. More importantly, it 
reduced the predictive influence of TCDD only at a region in the space immediately 
surrounding it (Fig. 2).  
Virtual query chemicals located in empty regions of the chemical space (Fig. 2, Table 5) 
were, as expected, characterized by low certainty values.  
Nine out of eleven chemicals initially selected for the validation set had a certainty equal at 1 
(including DEHP and Indomethacin) for all the values of the sigma parameter and could 
therefore be regarded as belonging to the applicability domain of the model. Predictions for 
DEHP and Indomethacin were always correct and the number of toxic chemicals 
characterized by a probability lower than 0.5 (i.e. false negatives) and safe chemicals 
characterized by a probability larger than 0.5 (i.e. false positives) were in the worst cases 
(Table 4) equal at two. Therefore we considered that the external predictivity of the model 
was satisfactory for the purpose of this article.  
 
3.2.3 Interpretation of molecular descriptors 
The model was characterized by the descriptors reported in table 6 together with their 
regression coefficients (referring to scaled and centered descriptors and scaled response 
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values). There is not a coefficient that clearly dominates the model. The descriptors try to 
capture different molecular characteristics (2-D autocorrelations, distribution of 
electronegativity, topology, shape, distribution of atomic mass) that statistically correlate with 
LOAEL values without indicating any clear mechanistic rationale for the biological activity.  
For instance, 2-D autocorrelations (Todeschini and Consonni, 2000) indicate that a positive 
autocorrelation between atomic masses at a path length of 4 (MATS4m, largest coefficient) 
and a negative autocorrelation between van der Waals volumes at a path length of 5 
(GATS5v) increases the LOAEL. The association of these fragments to a given toxicological 
mechanism is very difficult because of the structural heterogeneity of the dataset. Similarly, 
the E3e descriptor that is related to the atom distribution along the third axis for the electronic 
Sanderson electronegativities (Todeschini and Consonni, 2000) indicates that the three 
dimensional arrangement of halogens plays a role in modulating the LOAEL. Despite these 
observations, the three-dimensional arrangement of electronegative atoms for the training set 
chemicals cannot be directly associated with a unique class of chemical reactivity because the 
different functional groups that characterize the molecules.  
The descriptor RDF050m, that posses the largest negative coefficient, does not provide any 
clear mechanistic insight either. It simply takes into account the occurrence of some linear 
dependence between the LOAEL of the chemicals and the molecular distribution of atomic 
mass calculated at a radius of 0.5 Å, from the geometrical center of each molecule 
(Todeschini and Consonni, 2000).  
WHIM descriptors G2u and G2m (Todeschini and Consonni, 2000) encode information 
about the symmetry of the molecule and their negative coefficients indicates that the higher 
the molecular symmetry the smaller the LOAEL values without identifying any mechanistic 
basis for the model. 
The QSAR model developed for this article is therefore purely statistical mainly because of 
the structural heterogeneity of the training set. Indeed, the training set chemicals could act by 
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means of large number of possible toxicological mechanisms whose thorough description by 
means of a QSAR model would require a much larger training set. In addition, the fact that 
LOAEL values cover a broad range of teratogenic effects also renders difficult any possible 
mechanistic interpretation. Indeed, complex endpoints such as teratogenesis are predictable 
through QSAR models only to a limited extent mainly because of the high number of 
potential toxicological mechanisms characterizing the available sets of chemicals  
(Grindon et al., 2008 ; Enoch et al. 2009). As a consequence, the possibilities of taking 
decisions on the only basis of QSAR information are markedly reduced, but QSAR models 
can still be useful in planning further testing, using the method we propose in this paper.  
 
3.3 Simulation of testing strategies 
For the two selected molecules, we evaluated all possible strategies whose number of tests 
ranged from one to four (chosen among the three in vitro tests and the reference in vivo test). 
Table 7 presents the results we obtained for each test. The performances of the in vitro tests, 
in terms of false positive and false negative rates were relatively similar.  
For DEHP and threshold concentrations from 3 10-3 to 0.6 mg/kg/day (-1.52 and -0.22 on a 
logarithmic scale), the simulation of testing strategies indicated that performing one test (in 
vitro or in vivo) was enough to confirm the absence of toxicity, with false negative rate of 0 
and false positive rate below 5%, which can be considered as acceptable. In contrast, for 
exposure concentrations 3 and 30 mg/kg/day, the simulation of testing strategies indicated 
that only the execution of the in vivo test could confirm the absence of toxicity with false 
negative rates and false positive rates below 10%. Using in vitro testing in a test strategy 
would generate a false positive rate over 20%, which may be unacceptable.  
The actual in vivo LOAEL for DEHP was measured at 100 mg/kg/day. Moreover, we dispose 
of results from a WEC test (Rhee et al., 2002), according to which the predicted LOAEL 
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(obtained by applying to the WEC test result the median ratio of the distribution of ratios 
between WEC test outputs and actual LOAELs) would be 2.5 mg/kg/day. 
Basing decision on WEC test output would result in a true negative for exposure 
concentrations from 3 10-3 to 0.6 mg/kg/day, but in a false positive for the two other 
scenarios. This is coherent with the estimation of statistical performance resulting from our 
strategies based on QSAR modeling.  
For indomethacin and exposure scenarios 0.5 and 4 mg/kg/day (-0.3 and 0.6 on a logarithmic 
scale), simulation of testing strategies indicated that performing only the in vivo test alone can 
permit to have false positive and negative rates below 0.05. Simulations for a single in vitro 
test indicated a false negative rate of about 0.1 and false positive rates beyond 0.2. For 
exposure concentration of 40 mg/kg/day (1.60 on a logarithmic scale), performing the in vivo 
test alone can permit to have false positive and negative rates below 0.06. Performing two in 
vitro tests would result in a false positive rate of about 0.16 and false negative rate of about 
0.065, which could be reasonable. Performing only one in vitro test would increase the false 
negative rate beyond 0.25 which could be problematic. Performing the three in vitro tests 
would be counterproductive, as the rate of false positive would be over 0.25. For exposure 
concentration of 400 mg/kg/day, performing two in vitro tests would permit to have false 
positive rate at 0 and false negative rates below 0.03. Performing reference test would lead to 
false positive rate of 0 and false negative rate around 0.01. Performing only one in vitro test 
would result in a false negative rate above 0.15.   
The experimental in vivo LOAEL for indomethacin was measured at 1 mg/kg/day and we 
could therefore compare our results with experimental findings from a WEC test, according to 
which the estimated LOAEL would be 2.5 mg/kg. Basing decision on WEC test output would 
consequently yield only true negatives and true positives for the threshold we selected. This is 




As a final remark it is important to point out the added value of simulating testing strategies 
on the basis of QSAR predictions. Indeed, if toxicological probabilities are simply equal to 
the percentage of toxic molecules in the dataset (i.e. if nothing could be inferred on the basis 
of structural similarity) the simulation of testing strategies is less accurate. For instance, for a 
threshold equal at 0.6 mg/kg/day the simulation of testing strategies for DEHP in the absence 
of QSAR modeling would indicate that the WEC test is the only valuable in vitro test to be 
performed. Such a result is not accurate. Indeed, the actual LOAEL value for DEHP is 167 
times higher than the threshold. This means that all in vitro tests would have a rate of false 
positive below 0.1, as we showed when basing testing strategies simulations on QSAR 
information.   
As far as indomethacin is concerned, the simulation of testing strategies without the support 
of QSAR results for a threshold of 0.5 mg/kg/day would indicate that performing only a WEC 
test is enough in order to have a false positive/negative rate below 10%. Interestingly, 
simulations of test results integrating the information coming from QSAR modeling, indicated 
that an in vivo test is necessary. The latter result is more consistent with experimental results 
since the adopted threshold is twice as lower than the gold-standard LOAEL (1 mg/kg/day) 
and carrying out only the WEC test (LOAELWEC = 2.5 mg/kg/day) would lead to a much 
higher false positive rate (43%). Moreover, for a threshold equal at 40 mg/kg/day the 
simulation of testing strategies for Indomethacin without QSAR information would suggest 
that only an in vivo test could yield a false positive/negative rate below 10%. On the other 
hand, the integration of QSAR information shows that performing two in vitro tests could be 
an acceptable solution. This result is confirmed by the fact that performing a small test battery 
composed by the WEC test and any other in vitro test would prove that Indomethacin is toxic 





Our methodology enables to integrate QSAR and simulation of testing strategies within a 
structured workflow. Decision-making could therefore be driven by tests outputs simulated as 
a function of the physico-chemical properties of the molecule and permitted the selection of 
the most convenient testing strategy. Our methodology can contribute to the reduction of 
animal testing requirements by proposing alternatives each time that it is statistically 
acceptable in terms of toxicological performances.  
In their paper about tiered testing strategies, Grindon et al. (2008), propose a toxicological 
evaluation with the three embryotoxicity assays we use in our study. According to their 
proposition, if any of these tests gives a positive result, then a decision on Classification and 
Labeling and/or Risk Assessment should take place and during their discussion they consider 
that the probability to give unacceptably high levels of false negative data is low. As 
complementary information to their work, the present study shows that the rate of false 
positive of the approach by Grindon et al. (2008) can become unacceptable, in particular 
when all the three in vitro tests are performed as we showed, for instance, for indomethacin 
(false positive rate greater than 25% for an exposure concentration equal at 40 mg/kg/day). 
Overtesting should be avoided and only one or two in vitro tests should be carried out when in 
vivo tests can be replaced. 
Since the statistical performances of the in vitro tests are relatively similar, when the 
simulation of testing strategies indicates that one in vitro test would be sufficient, the 
selection of the test to be adopted cannot be based on statistical performances. Therefore, 
another criterion should be used (i.e. monetary and/or ethical cost). For instance, Grindon et 
al. (2008) showed that the EST test should be preferred to the two other tests because it is the 
only one that can be adapted to high-throughput studies without involving the killing of large 
numbers of pregnant animals. 
The QSAR model we derived organized the chemical space in a way that enabled the 
derivation of reasonable predictions for toxicological probabilities. However, the adopted 
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model was very local and it was therefore crucial to define its applicability domain thanks to 
the methodology described in Pery et al. (2009). In particular, this methodology, allowed to 
define the applicability domain of the model for a chemical space that yields reliable 
predictions by strongly limiting the number of prediction outliers thanks to Gaussians 
distribution for predictive certainty centered on each training set chemicals 
Thanks to this approach it was therefore possible to derive correct probabilistic predictions for 
the two analyzed molecules while being sure that query chemicals located far from the 
training set chemicals were characterized by a high predictive uncertainty. As can be seen in 
Figure 2, the predictive influence of TCDD was limited to the region immediately 
surrounding the chemical and virtual query chemicals probing empty spaces lying between 
TCDD and the rest of the training set are characterized by a predictive certainty lower than 1 
and therefore outside the applicability domain of the model. (Table 4, Fig. 1).     
Our methodology can be adapted to any other toxicological endpoint, provided that a relevant 
QSAR model can be derived together with available in vitro information for several 
chemicals (about 20) with both reference test (i.e. “gold standard” in vivo test) and in vitro 
results. The methodology we presented can also be adapted to toxicological “gold standard” 
other than tests on animals, such as thresholds derived from clinical trials.  
In conclusion, our paper presents an original method coupling QSAR modeling and 
simulation of toxicologial testing. The selection of a relevant testing strategy is driven not 
only by test performance, but also by the particular physico-chemical properties of the 
molecules under investigation. The selection of the optimal testing strategy is then a trade-off 
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Table 1 Chemicals used to develop and test the QSAR model adopted for our investigation. 
Activities are given as decimal Log of the LOAEL expressed in mg/kg/day. Training set 



















131-70-4 Monobutyl phthalate 2.40 1 
138261-41-3 Imidacloprid 1.93 1 
1746-01-6 Tetrachlorodibenzodioxin -3.30 1 
17804-35-2 Benomyl 1.75 1 
1836-75-5 Nitrofen 0.80 1 
22071-15-4 Ketoprofen 0.00 1 
24602-86-6 Tridemorph 0.00 1 
26171-23-3 Tolmetin 1.31 1 
26761-40-0 Diisodecyl phthalate 3.00 1 




50-06-6 Phenobarbital 1.60 1 
50471-44-8 Vinclozolin 2.00 1 
5104-49-4 Flurbiprofen 1.00 1 
52315-07-8 Cypermethrin 1.70 1 
53164-05-9 Acemetacin -0.30 1 
58-08-2 Caffeine 0.78 1 
58-89-9 Lindane 1.30 1 




83-79-4 Rotenone 0.70 1 
84-69-5 Diisobutyl phthalate 2.70 1 
84-74-2 Dibutyl phthalate 2.70 1 
87237-48-7 Haloxyfop-etotyl 1.00 1 
87-51-4 Indoleacetic acid 1.70 1 
94361-06-5 Cyproconazole 2.00 1 
107534-96-3 Tebuconazole 1.78 2 
117-81-7 Diethylhexyl phthalate 2.00 2 




53-86-1 Indomethacin 0.00 2 
54-31-9 Furosemide 1.70 2 
58138-08-2 Tridiphane 2.00 2 
69806-50-4 Fluazifop-butyl 2.30 2 
76-44-8 Heptachlor 0.48 2 
84-66-2 Diethyl Phthalate 3.39 2 





Table 2. Toxicological data that allowed the derivation of statistical distributions describing 
the ratio between in vitro and in vivo results. Such distributions are necessary in order to make 
possible a comparison between results yielded by different experimental systems which are 
expressed in different units.  
CAS 
Number Name LOAEL 




79-81-2 retinol palmitate 206 mg/kg/day 25 µg/ml WEC Ritchie et al., 1998. 
4759-48-2 13-cis-retinoic acid 50 mg/kg/day 0,5 µg/ml WEC Ritchie et al., 1998. 
68-26-8 vitamin A 37,5 mg/kg/day 375 ng/ml WEC Ritchie et al., 1998. 
302-79-4 all-trans retinoic acid 5 mg/kg/day 0,5 µg/ml WEC Morris et al., 1976. 
50-78-2 aspirin 250 mg/kg/day 10 µg/ml WEC Cicurel et al., 1988. 
50-02-2 dexamethasone 0,08 mg/kg/day 5 µg/ml WEC Hansen et al., 1994 
53-86-1 methazine 1 mg/kg/day 1 µg/ml WEC Cuberland et al., 1994. 
147-24-0 diphenhydramine 100 mg/kg/day 1 µg/ml WEC Cuberland et al., 1994. 
58-08-2 caffeine 6 mg/kg/day 100 µg/ml WEC Cicurel et al., 1988 
305-03-3 chlorambucil 6 mg/kg/day 10 µg/ml WEC Cicurel et al., 1988 
66-81-9 cycloheximide 1 mg/kg/day 0,03 µg/ml WEC Cicurel et al., 1988 
50-02-2 dexamethasone 0,08 mg/kg/day 270 µg/ml WEC Cicurel et al., 1988 
439-14-5 diazepam 500 mg/kg/day 100 µg/ml WEC Cicurel et al., 1988 
57-41-0 diphenylhydantoin 100 mg/kg/day 100 µg/ml WEC Cicurel et al., 1988 
96-45-7 N,N'-ethylene thiourea 30 mg/kg/day 100 µg/ml WEC 
Cicurel et al., 1988 
51-21-8 fluorouracil 5 mg/kg/day 0,6 µg/ml WEC Cicurel et al., 1988 
50-35-1 thalidomide 100 mg/kg/day 1000 µg/ml WEC Cicurel et al., 1988 
58-55-9 theophylline 258,6 mg/kg/day 100 µg/ml WEC Cicurel et al., 1988 
75-07-0 acetaldehyde 240 mg/kg/day 45 µg/ml WEC Menegola et al., 2001. 
84-74-2 dibutylphtalate  500 mg/kg/day 10 µg/ml WEC Rhee et al., 2002. 
50-28-2 estradiol 0,225 mg/kg/day 30 ug/ml WEC Bowden et al., 1993. 
4759-48-2 13-cis-retinoic acid 50 mg/kg/day 0,08 µg/ml MM Renault et al., 1989. 
127-07-1 hydroxycarbamide 200 mg/kg/day 14,3 µg/ml MM Renault et al., 1989. 
50-78-2 aspirin 250 mg/kg/day 1436 µg/ml MM Renault et al., 1989 
50-02-2 dexamethasone 0,08 mg/kg/day 30,5 µg/ml MM Renault et al., 1989 
53-86-1 methazine 1 mg/kg/day 4 µg/ml MM Flint et al., 1984. 
147-24-0 diphenhydramine 100 mg/kg/day 48,8 µg/ml MM Renault et al., 1989 
84-74-2 dibutylphtalate 500 mg/kg/day 27,47 µg/ml MM Rhee et al., 2002. 
85-68-7 benzylbutyl hthalate 270 mg/kg/day 412,24 µg/ml MM Rhee et al., 2002 
305-03-3 chlorambucil 6 mg/kg/day 2,6 µg/ml MM Renault et al., 1989 
56-75-7 chloramphenicol 2500 mg/kg/day 230 µg/ml MM Flint et al., 1984. 
2921-88-2 chlorpyrifos 3 mg/kg/day 16 µg/ml MM Cosenza et al., 1995. 
50-18-0 cyclophosphamide 10 mg/kg/day 325 µg/ml MM Flint et al., 1984. 
439-14-5 diazepam 500 mg/kg/day 150 µg/ml MM Flint et al., 1984. 
60-00-4 Ethylenediaminetetra 
acetic acid 954 mg/kg/day 2,8 µg/ml MM 
Flint et al., 1984. 
50-00-0 Formaldehyde 8 mg/kg/day 5,3 µg/ml MM Renault et al., 1989. 
302-79-4 all-trans retinoic acid 5 mg/kg/day 0,000105 µg/ml EST Spielmann et al., 1997. 
127-07-1 hydroxycarbamide 200 mg/kg/day 1,7 µg/ml EST Spielmann et al., 1997. 
50-78-2 aspirin 250 mg/kg/day 248 µg/ml EST Spielmann et al., 1997. 
50-02-2 dexamethasone 30,5 µg/ml 18,3 µg/ml EST Spielmann et al., 1997. 
53-86-1 methazine 1 µg/ml 66 µg/ml EST Spielmann et al., 1997. 
147-24-0 diphenhydramine 1 µg/ml 6,7 µg/ml EST Spielmann et al., 1997. 
58-08-2 caffeine 100 µg/ml 185 µg/ml EST Spielmann et al., 1997. 
50-18-0 cyclophosphamide 325 µg/ml 21 µg/ml EST Newall et al., 1996. 
55-98-1 busulfan 100 mg/kg/day 4,6 µg/ml EST Spielmann et al., 1997. 
51-21-8 fluorouracil 0,6 µg/ml 0,029 µg/ml EST Spielmann et al., 1997. 
50-35-1 
thalidomide 1000 µg/ml 67 µg/ml EST 
Zur Nieden et al., 
2001. 
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Fig. 2. Plot of the orthogonal latent variables LV1 and LV2. Training set chemicals are represented by black diamonds, DEHP and Indomethacin 
are represented as a white square and a white circle respectively. The isolated point on the left represents TCDD and the dashed circle represents 
. A query chemical located at a distance equal at  (i.e. on the dashed lines) from TCDD will be characterized by a predictive certainty 
equal at 1/e ≈ 0.37 where e is the Neperian number. The grey dots represent virtual query chemical probing empty spaces: for all of them the 
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  Threshold for Log 
LOAEL 

-1.52 2.7 -0.3 0.7 
-0.22 0.7 0.6 1.97 
0.48 1.97 1.6 1.24 
1.48 
 
1.24 2.6 0.77 
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Table 4 Toxicological probabilities for the test set corresponding to the different scenarios for 
DEHP and Indomethacin. Chemicals for which the LOAEL is below the threshold (i.e. toxic 

















107534-96-3 0 1 107534-96-3 0 1 
117-81-7 0 1 117-81-7 0 1 
13710-19-5 0 1 13710-19-5 0 1 
32774-16-6 0.04 0.14 32774-16-6 0.07 0 
53-86-1 0 1 53-86-1 0 1 
54-31-9 0 1 54-31-9 0 1 
58138-08-2 0 1 58138-08-2 0 1 
69806-50-4 0 1 69806-50-4 0 1 
76-44-8 0 1 76-44-8 0.04 0.48 
84-66-2 0 1 84-66-2 0 1 





107534-96-3 0 1 107534-96-3 0.04 1 
117-81-7 0 1 117-81-7 0.05 1 
13710-19-5 0 1 13710-19-5 0.12 1 
03274-16-6 0.07 0 03274-16-6 0.15 0 
53-86-1 0 1 53-86-1 0.24 1 
54-31-9 0 1 54-31-9 0.16 1 
58138-08-2 0 1 58138-08-2 0.01 1 
69806-50-4 0 1 69806-50-4 0.07 1 
76-44-8 0.04 0.48 76-44-8 0.01 0.93 
84-66-2 0 1 84-66-2 0.03 1 





107534-96-3 0.04 1 107534-96-3 0.18 1 
117-81-7 0.05 1 117-81-7 0.10 1 
13710-19-5 0.12 1 13710-19-5 0.56 1 
32774-16-6 0.15 0 32774-16-6 0.48 0 
53-86-1 0.24 1 53-86-1 0.76 1 
54-31-9 0.16 1 54-31-9 0.73 1 
58138-08-2 0.01 1 58138-08-2 0.1 1 
69806-50-4 0.07 1 69806-50-4 0.3 1 
76-44-8 0.01 0.93 76-44-8 0.91 0.83 
84-66-2 0.03 1 84-66-2 0.19 1 





107534-96-3 0.18 1 107534-96-3 0.88 1 
117-81-7 0.10 1 117-81-7 0.42 1 
13710-19-5 0.56 1 13710-19-5 1 1 
32774-16-6 0.48 0 32774-16-6 0.85 0 
53-86-1 0.76 1 53-86-1 1 1 
54-31-9 0.73 1 54-31-9 1 1 
58138-08-2 0.1 1 58138-08-2 1 1 
69806-50-4 0.3 1 69806-50-4 1 1 
76-44-8 0.91 0.83 76-44-8 0.93 0.55 
84-66-2 0.19 1 84-66-2 0.99 1 




Table 5 Predictive certainty for virtual query chemicals computed for  = 1.24. All the 








C1 < 0.1 











Table 6 Retained descriptors and regression coefficients of the retained QSAR model. 










MATS4m 2D-autocorrelation  0.19377 
E3e WHIM  0.17081 
JhetZ Topological   0.158696 
RDF050m RDF -0.149818 
G2m WHIM -0.144327 
GATS5v 2D-autocorrelation -0.138099 
G2u WHIM -0.135932 
RDF080m RDF -0.11942 
G(O..Cl) Geometrical -0.114555 
GATS4v 2D-autocorrelation -0.110849 
Mor31u 3d-Morse  0.10955 
E1v WHIM -0.0825062 
Mor19v 3d-Morse  0.0607 
G1m WHIM -0.0532846 
R1e GETAWAY  0.0464452 
















































3-30 10-3 0 0 0 0.01 0 0.02 0 0.02 
0.6 0 0 0 0.02 0 0.05 0 0.05 
3 0.003 0.002 0.2 0.01 0.23 0.01 0.24 0.01 




























0.5 0.04 0.02 0.21 0.03 0.24 0.03 0.25 0.03 
4 0.04 0.03 0.22 0.10 0.24 0.11 0.24 0.11 
40 0.04 0.06 0.09 0.24 0.09 0.26 0.09 0.26 
400 0 0.001 0 0.13 0 0.17 0 0.17 
 
 
 
